# Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults

> **NCT00740155** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 154 (actual)

## Conditions studied

- Dengue Virus
- Dengue Fever
- Dengue Hemorrhagic Fever
- Dengue Diseases

## Interventions

- **BIOLOGICAL:** Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)
- **BIOLOGICAL:** Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)
- **BIOLOGICAL:** Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)
- **BIOLOGICAL:** Tetravalent CYD-1,2,3,4 Dengue (Vero)
- **BIOLOGICAL:** JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)

## Key facts

- **NCT ID:** NCT00740155
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-10
- **Final completion:** 2010-01
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2015-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00740155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00740155, "Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00740155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*